GLP1R and diabetes mellitus: In this nationally representative sample of obese US adults without diabetes (NHANES 2011-2018; unweighted n = 6,065; weighted ≈69 million), no GLP-1 receptor agonist use was reported, reflecting minimal community uptake during this period.